Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2017 Jun 13;16(9):1954–1966. doi: 10.1158/1535-7163.MCT-17-0139

Figure 6. Wnt inhibition enhances the efficacy of imatinib in vitro and in vivo.

Figure 6

(A) Cell viability assay of human GIST cell lines at 72h after the indicated treatment. (B) Immunoblots of whole-cell lysates of GIST T1 cells 24h after the indicated treatment. (C) Tumor weight in KitV558Δ/+ mice treated for 2 weeks with vehicle (Veh), imatinib (Imat), G007-LK plus imatinib, or G007-LK alone. n=4–5 mice per group. Medians are indicated. (D) Immunoblots of whole-cell lysates from vehicle or treated KitV558Δ/+ tumors. (E) Representative H&E, Ki-67 staining and quantification in KitV558Δ/+ tumors after 2 weeks of the indicated treatment. Scale bar, 50 μm. Bars indicate means ± SEM. Student’s t test; *P < 0.05, **P < 0.01, ***P < 0.001.